Literature DB >> 1998655

Identification of the base substitution responsible for the Ag(x/y) polymorphism of apolipoprotein B-100.

M J Wu1, E Bütler, R Bütler, V N Schumaker.   

Abstract

The identification of the base substitution responsible for Ag(x/y) completes the description of the antigen group polymorphisms associated with the apolipoprotein B polypeptide. Surprisingly, all five antigen group polymorphisms alter restriction endonuclease cleavage sites and have associated restriction fragment length polymorphisms, thereby providing a convenient alternative for antigen group phenotyping.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1998655     DOI： 10.1161/01.atv.11.2.379

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN： 1049-8834


  4 in total

1.  Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia.

Authors:  D A Hardman; C R Pullinger; R L Hamilton; J P Kane; M J Malloy
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

2.  Two amino acid substitutions in apolipoprotein B are in complete allelic association with the antigen group (x/y) polymorphism: evidence for little recombination in the 3' end of the human gene.

Authors:  A M Dunning; H H Renges; C F Xu; R Peacock; R Brasseur; G Laxer; M J Tikkanen; R Bütler; N Saha; A Hamsten
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

3.  Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans.

Authors:  Norihisa Sakamoto; Kazuhide Tsuji; Linda M Muul; Ann M Lawler; Emanuel F Petricoin; Fabio Candotti; Julia A Metcalf; Jorge A Tavel; H Clifford Lane; Walter J Urba; Bernard A Fox; Ajit Varki; Joan K Lunney; Amy S Rosenberg
Journal:  Blood       Date:  2007-03-29       Impact factor: 22.113

4.  Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity.

Authors:  C R Pullinger; L K Hennessy; J E Chatterton; W Liu; J A Love; C M Mendel; P H Frost; M J Malloy; V N Schumaker; J P Kane
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.